Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C i.v. every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continuous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxicity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.
Reichman
B
B
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Markman
M
M
Hakes
T
T
Rubin
S
S
Jones
W
W
Curtin
J
J
Barakat
R
R
Almadrones
L
L
Lewis
J L
JL
Hoskins
W
W
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000628:therapy*; D010984:Platinum / Q000627:therapeutic use*; D016879:Salvage Therapy
D010984:Platinum; D016685:Mitomycin; D005472:Fluorouracil